https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12757 Wed 11 Apr 2018 09:18:59 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31060 14 days) exposure to a PDA were compared to control infants without a PDA. Results: Thirty out of 189 infants had prolonged exposure to a PDA. The left heart remodeled to a larger and more spherical shape and thus significantly increased in volume. Most changes occurred in the first 4 weeks, plateaued, and then returned to control values. Systolic function and estimates of filling pressure increased and effective arterial elastance reduced with a PDA, however contractility was unchanged. Wall thickness increased after 4 weeks of increased volume exposure. Conclusion: The preterm PDA induces early and significant remodeling of the left heart. A compensated cardiac physiology was seen with preserved systolic function, suggesting adaptive rather than pathological remodeling changes with prolonged exposure to a PDA.]]> Wed 10 Nov 2021 15:14:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33273 2+ release, leading to sarcoplasmic reticulum Ca²⁺ depletion, reduced cardiac function, and providing cell protection against ischemia-reperfusion injury. Anesthetic activation of ryanodine receptor 2 is poorly defined, leaving aspects of the protective mechanism uncertain. Methods: Ryanodine receptor 2 from the sheep heart was incorporated into artificial lipid bilayers, and their gating properties were measured in response to five halogenated anesthetics. Results: Each anesthetic rapidly and reversibly activated ryanodine receptor 2, but only from the cytoplasmic side. Relative activation levels were as follows: halothane (approximately 4-fold; n = 8), desflurane and enflurane (approximately 3-fold,n = 9), and isoflurane and sevoflurane (approximately 1.5-fold, n = 7, 10). Half-activating concentrations (Kₐ) were in the range 1.3 to 2.1 mM (1.4 to 2.6 minimum alveolar concentration [MAC]) with the exception of isoflurane (5.3 mM, 6.6 minimum alveolar concentration). Dantrolene (10 µM with 100 nM calmodulin) inhibited ryanodine receptor 2 by 40% but did not alter the Kₐ for halothane activation. Halothane potentiated luminal and cytoplasmic Ca²⁺ activation of ryanodine receptor 2 but had no effect on Mg²⁺ inhibition. Halothane activated ryanodine receptor 2 in the absence and presence (2 mM) of adenosine triphosphate (ATP). Adenosine, a competitive antagonist to ATP activation of ryanodine receptor 2, did not antagonize halothane activation in the absence of ATP. Conclusions: At clinical concentrations (1 MAC), halothane desflurane and enflurane activated ryanodine receptor 2, whereas isoflurane and sevoflurane were ineffective. Dantrolene inhibition of ryanodine receptor 2 substantially negated the activating effects of anesthetics. Halothane acted independently of the adenine nucleotide-binding site on ryanodine receptor 2. The previously observed adenosine antagonism of halothane activation of sarcoplasmic reticulum Ca²⁺ release was due to competition between adenosine and ATP, rather than between halothane and ATP.]]> Mon 24 Sep 2018 13:26:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40786 Mon 18 Jul 2022 16:07:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45514 Mon 07 Nov 2022 11:11:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39651 Fri 17 Jun 2022 13:19:10 AEST ]]>